ARDT Ardent Health Partners, Inc.

NYSE ardenthealth.com


$ 14.58 $ 0.09 (0.62 %)    

Thursday, 16-Oct-2025 15:59:53 EDT
QQQ $ 597.08 $ 0.00 (0 %)
DIA $ 458.96 $ 0.00 (0 %)
SPY $ 658.63 $ 0.00 (0 %)
TLT $ 91.28 $ 0.00 (0 %)
GLD $ 395.96 $ 0.00 (0 %)
$ 14.59
$ 14.53
$ 13.25 x 2
$ 14.95 x 2
-- - --
$ 10.10 - $ 20.19
258,642
na
2.09B
$ 0.33
$ 8.19
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-06-2025 06-30-2025 10-Q
2 05-07-2025 03-31-2025 10-Q
3 02-27-2025 12-31-2024 10-K
4 11-07-2024 09-30-2024 10-Q
5 08-14-2024 06-30-2024 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

Goldman Sachs analyst Scott Fidel initiates coverage on Ardent Health (NYSE:ARDT) with a Neutral rating and announces Price...

Core News & Articles

UBS analyst A.J. Rice initiates coverage on Ardent Health (NYSE:ARDT) with a Buy rating and announces Price Target of $17.

Core News & Articles

- SEC Filing

Core News & Articles

JP Morgan analyst Benjamin Rossi maintains Ardent Health (NYSE:ARDT) with a Neutral and lowers the price target from $18 to ...

Core News & Articles

Keybanc analyst Matthew Gillmor maintains Ardent Health (NYSE:ARDT) with a Overweight and lowers the price target from $24 t...

Core News & Articles

Ardent Health (NYSE:ARDT) affirms FY2025 GAAP EPS guidance from $1.73-$2.01 to $1.73-$2.01 vs $1.92 analyst estimate. Affirms F...

Core News & Articles

Ardent Health Partners (NYSE:ARDT) reported quarterly earnings of $0.52 per share which met the analyst consensus estimate. Thi...

Core News & Articles

B of A Securities analyst Kevin Fischbeck downgrades Ardent Health (NYSE:ARDT) from Neutral to Underperform and lowers the p...

Core News & Articles

Ardent Health Partners, Inc. (NYSE:ARDT) ("Ardent Health" or the "Company"), a leading provider of healthcare i...

Core News & Articles

Stephens & Co. analyst Scott Fidel reiterates Ardent Health Partners (NYSE:ARDT) with a Overweight and maintains $21 pr...

Core News & Articles

RBC Capital analyst Ben Hendrix reiterates Ardent Health Partners (NYSE:ARDT) with a Outperform and maintains $21 price target.

Core News & Articles

Guggenheim analyst Jason Cassorla maintains Ardent Health Partners (NYSE:ARDT) with a Buy and raises the price target from $...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION